AIMS: To examine outcomes in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) at US sites versus sites outside the US (OUS). METHODS AND RESULTS: In the HORIZONS-AMI trial 3,602 STEMI patients in 11 countries were randomised to primary PCI with bivalirudin versus heparin + glycoprotein IIb/IIIa inhibitors. US patients (n=814) had more diabetes, prior infarction, prior bypass surgery, and renal insufficiency. OUS patients (n=2,788) had longer door-to-balloon times, more radial access, fewer bypass surgeries, and were discharged more often on beta-blockers and statins. At three years US patients had higher mortality (9.7% vs. 6.0%, p=0.0003), reinfarction (10.2% vs. 6.4%, p=0.001), major adverse cardiac events (MACE; 28.2% vs. 20.1%, p<0.0001), major bleeding (16.9% vs. 6.4%, p<0.0001) and net adverse clinical events (NACE; 36.6% vs. 23.8%, p<0.0001), which persisted after adjusting for baseline risk. CONCLUSIONS: In the HORIZONS-AMI trial, STEMI patients undergoing primary PCI at US versus OUS sites had higher rates of adverse events, which persisted after adjusting for baseline risk. The reasons for these differences are not clear but may be due to unmeasured confounders, different thresholds for event reporting, or valid differences in systems of care and treatments.
RCT Entities:
AIMS: To examine outcomes in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) at US sites versus sites outside the US (OUS). METHODS AND RESULTS: In the HORIZONS-AMI trial 3,602 STEMI patients in 11 countries were randomised to primary PCI with bivalirudin versus heparin + glycoprotein IIb/IIIa inhibitors. US patients (n=814) had more diabetes, prior infarction, prior bypass surgery, and renal insufficiency. OUSpatients (n=2,788) had longer door-to-balloon times, more radial access, fewer bypass surgeries, and were discharged more often on beta-blockers and statins. At three years US patients had higher mortality (9.7% vs. 6.0%, p=0.0003), reinfarction (10.2% vs. 6.4%, p=0.001), major adverse cardiac events (MACE; 28.2% vs. 20.1%, p<0.0001), major bleeding (16.9% vs. 6.4%, p<0.0001) and net adverse clinical events (NACE; 36.6% vs. 23.8%, p<0.0001), which persisted after adjusting for baseline risk. CONCLUSIONS: In the HORIZONS-AMI trial, STEMI patients undergoing primary PCI at US versus OUS sites had higher rates of adverse events, which persisted after adjusting for baseline risk. The reasons for these differences are not clear but may be due to unmeasured confounders, different thresholds for event reporting, or valid differences in systems of care and treatments.
Authors: Deepak L Bhatt; Michael Miller; Eliot A Brinton; Terry A Jacobson; Ph Gabriel Steg; Steven B Ketchum; Ralph T Doyle; Rebecca A Juliano; Lixia Jiao; Craig Granowitz; Jean-Claude Tardif; Brian Olshansky; Mina K Chung; C Michael Gibson; Robert P Giugliano; Matthew J Budoff; Christie M Ballantyne Journal: Circulation Date: 2019-11-11 Impact factor: 29.690
Authors: Nikola Kos; Ivan Zeljković; Tomislav Krčmar; Karlo Golubić; Fran Šaler; Marijan Erceg; Diana Delić-Brkljačić; Nikola Bulj Journal: Cardiol Res Pract Date: 2021-11-24 Impact factor: 1.866
Authors: Muthiah Vaduganathan; Robert A Harrington; Gregg W Stone; Ph Gabriel Steg; C Michael Gibson; Christian W Hamm; Matthew J Price; Jayne Prats; Efthymios N Deliargyris; Kenneth W Mahaffey; Harvey D White; Deepak L Bhatt Journal: Circ Cardiovasc Interv Date: 2016-06 Impact factor: 6.546
Authors: Jorge Solano-López; José Luis Zamorano; Ana Pardo Sanz; Ignacio Amat-Santos; Fernando Sarnago; Enrique Gutiérrez Ibañes; Juan Sanchis; Juan Ramón Rey Blas; Joan Antoni Gómez-Hospital; Sandra Santos Martínez; Nicolás Manuel Maneiro-Melón; Roberto Mateos Gaitán; Jessika González D'Gregorio; Luisa Salido; José L Mestre; Marcelo Sanmartín; Ángel Sánchez-Recalde Journal: Rev Esp Cardiol Date: 2020-09-17 Impact factor: 4.753